← Leaderboards
Radosveta P Koldamova
University Of Pittsburgh At Pittsburgh
$12,908,953
Attributed
$22,364,381
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,364,381 · 10
By mechanism
R01$15,595,287 · 6
RF1$6,013,456 · 2
R56$440,615 · 1
R21$315,023 · 1
Top collaborators
- Iliya Lefterov19 shared
- Fabrisia Ambrosio5 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Iliya Lefterov$9,615,606
- Robert D Nicholls$6,020,455
- Fabrisia Ambrosio$15,553,662
- Leaf Huang$16,174,553
- David Alan Vorp$12,987,916
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseAffectPathogenesisBrainMediatingNeuronsAllelesLate Onset Alzheimer DiseaseGene ExpressionMolecularProteinsAmyloidNerve DegenerationImpaired CognitionGenesDementiaLinkAgingBaseCholesterolDepositionNeurofibrillary TanglesPrevent
Grant awards (39)
ncRNAs in plasma EVs of AD patients and their discriminatory power as biomarkers$1,437,361
RF1 · FY2025 · AG
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$691,227
R01 · FY2025 · AG · contact PI
Physical exercise and Blood-brain communication: exosomes, Klotho and choroid plexus$754,220
R01 · FY2024 · AG · contact PI
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$718,053
R01 · FY2024 · AG · contact PI
Physical exercise and Blood-brain communication: exosomes, Klotho and choroid plexus$764,075
R01 · FY2023 · AG · contact PI
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$729,819
R01 · FY2023 · AG · contact PI
ncRNAs in plasma EVs of AD patients and their discriminatory power as biomarkers$2,297,526
RF1 · FY2022 · AG
Physical exercise and Blood-brain communication: exosomes, Klotho and choroid plexus$768,387
R01 · FY2022 · AG · contact PI
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$706,518
R01 · FY2022 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$635,903
R01 · FY2022 · AG
Physical exercise and Blood-brain communication: exosomes, Klotho and choroid plexus$772,517
R01 · FY2021 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$632,773
R01 · FY2021 · AG
Physical exercise and Blood-brain communication: exosomes, Klotho and choroid plexus$782,487
R01 · FY2020 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$624,948
R01 · FY2020 · AG
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$674,908
R01 · FY2019 · AG
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$634,993
R01 · FY2018 · AG
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$499,887
R01 · FY2018 · ES
Age dependent APOE isoform specific effect on immune receptor mediated$344,102
RF1 · FY2018 · AG
Age dependent APOE isoform specific effect on immune receptor mediated phagocytosis in brain$1,934,467
RF1 · FY2017 · AG
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$510,051
R01 · FY2017 · ES
APOE orchestrated ''molecular signatures'' in aging brain and AD - the contribution of APOE2$440,615
R56 · FY2017 · AG
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$519,919
R01 · FY2016 · ES
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$529,500
R01 · FY2015 · ES
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$355,297
R01 · FY2015 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$506,600
R01 · FY2014 · ES
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$366,252
R01 · FY2014 · AG · contact PI
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$110,000
R01 · FY2014 · AG · contact PI
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$293,493
R01 · FY2013 · AG · contact PI
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$55,295
R01 · FY2013 · AG · contact PI
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$310,575
R01 · FY2012 · AG · contact PI
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models$310,575
R01 · FY2011 · AG · contact PI
Role of ABCA1 in neurodegeneration$250,496
R01 · FY2011 · AG · contact PI
Role of ABCA1 in neurodegeneration$258,101
R01 · FY2010 · AG · contact PI
Role of ABCA1 in neurodegeneration$34,000
R01 · FY2010 · AG · contact PI
Role of ABCA1 in neurodegeneration$260,708
R01 · FY2009 · AG · contact PI
Role of ABCA1 in neurodegeneration$253,942
R01 · FY2008 · AG · contact PI
Role of ABCA1 in neurodegeneration$279,768
R01 · FY2007 · AG · contact PI
ABCA1: A Potential Therapeutic Target for AD$143,981
R21 · FY2006 · AG · contact PI
ABCA1: A Potential Therapeutic Target for AD$171,042
R21 · FY2005 · AG